

The logo for DSM, consisting of the letters "DSM" in a bold, blue, sans-serif font.

PRESS RELEASE

Crucell and DSM Intensify Collaboration and Development of PER.C6[®] Human Cell Line

Sittard/Leiden, The Netherlands, February 9, 2007 – DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have further intensified their PER.C6[®] collaboration, by executing an agreement to expand the existing commercial relationship to include new classes of proteins, including biosimilar protein products. As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

Since December 2002, DSM Biologics and Crucell are jointly out licensing PER.C6[®] human cell line to third parties as a production platform for monoclonal antibodies and recombinant proteins. The parties recently established the PERCIVIA PER.C6[®] Development Center in Cambridge, Mass, USA as a joint venture to further develop the PER.C6[®] cell line and provide a unique solution for the production of pharmaceutical proteins to licensees utilizing the PER.C6[®] human cell line in the biotech industry.

About PER.C6[®] technology

The PER.C6[®] technology is a cell line developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6[®] technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. These characteristics, combined with its ability to support the growth of both human and animal viruses, make PER.C6[®] technology the biopharmaceutical production technology of choice for Crucell's current and potential pharmaceutical and biotechnology partners.

About PERCIVIA

PERCIVIA PER.C6[®] Development Center LLC is a joint venture between DSM and Crucell. The Center has approximately 47,000 square feet of laboratory space in Cambridge, Mass, and will have a staff of 50 highly skilled staff engaged in the development and optimization of the human PER.C6[®] cells as an expression platform for proteins and monoclonal antibodies for therapeutic use. This center of excellence will provide a fully integrated technology platform, and true unique solutions for the production of pharmaceutical proteins, to the biotech industry and scientific community. This PER.C6[®] technology platform will comprise cell line generation technology, cell culture media development, upstream and downstream processes, equipment selection, scale-up, technology transfer, and regulatory support. PERCIVIA will have dedicated space for PER.C6[®] cell line users to experience the technology hands on.

DSM



About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6[®] production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology and services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6[®] human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, The Netherlands, was established in 1986 and has a strong track record in using a broad range of cell lines (PER.C6[®] CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6[®] human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. For more information, please visit www.dsmbiologics.com.

About DSM

DSM is [active worldwide](#) in nutritional and pharma ingredients, performance materials and industrial chemicals. The company creates innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end markets and applications such as human and animal nutrition and health, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics (E&E). DSM's strategy, named *Vision 2010 – Building on Strengths*, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. Market-driven growth, innovation and increased presence in emerging economies are key drivers of this strategy. The group has annual sales of approximately EUR 8 billion and employs around 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia and the Americas.

The logo for DSM, consisting of the letters "DSM" in a bold, blue, sans-serif font.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release.

Crucell has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". Crucell prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

DSM Pharmaceuticals Products

Terry Novak
Chief Marketing Officer
DSM Pharmaceuticals Inc. & Biologics
Tel. +1 973 257 8471
Terry.Novak@dsm.com

DSM Biologics

Brad Carlson
Vice President, Marketing, Sales & NBD
Tel. +1 585 624 3844
Brad.Carlson@dsm.com

DSM Biologics

Marcel Lubben
New Business Development
Europe and Asia
+31 46 47 73343
Marcel-m.lubben@dsm.com

Crucell N.V.

Leon Kruimer
Chief Financial Officer
Tel. +31(0)71 524 8722
ir@crucell.com

Barbara Mulder
Tel: 31-(0) 71 524 8718
barbara.mulder@crucell.com

Crucell N.V. in the USA:

Thomas Redington
Tel. +1 212 926 1733
tredington@redingtoninc.com